All congress activities

This poster, presented at SSIEM 2026, outlines the design of the EPIPHENY Phase 3b study, which evaluates the effects of long-term sepiapterin on neurocognitive function in children with phenylketonuria (PKU)

This poster, presented at SSIEM 2026, examines the long-term efficacy and safety of sepiapterin in people with phenylketonuria (PKU) and controlled blood phenylalanine (Phe) levels

This poster, presented at SSIEM 2026, examines the efficacy and safety of sepiapterin in individuals with phenylketonuria (PKU) and baseline phenylalanine (Phe) levels ≥900 µmol/L, including its impact on blood Phe levels and dietary protein tolerance

This poster, presented at SSIEM 2026, evaluates mixing and compatibility studies of sepiapterin to inform additional administration approaches for people with phenylketonuria (PKU)

This poster, presented at SSIEM 2026, discusses null PAH variants in individuals with phenylketonuria (PKU) and their association with disease severity and treatment response

This poster, presented at SSIEM 2026, highlights the efficacy and safety of sepiapterin in participants with phenylketonuria (PKU) who were already receiving sapropterin at study screening in the AMPLIPHY Phase 3 study

This symposium, presented at SIMD 2026, reviews the latest clinical trial and real-world evidence of sepiapterin across a broad spectrum of patients with phenylketonuria (PKU)

This infographic, which supports the poster presented at GMDI 2026, highlights findings from the APHENITY extension study evaluating the long-term effects of sepiapterin treatment on dietary phenylalanine tolerance in children aged ≤2 years with phenylketonuria (PKU)

This poster, presented at GMDI 2026, highlights findings from the APHENITY extension study evaluating the long-term effects of sepiapterin treatment on dietary phenylalanine tolerance in children aged ≤2 years with phenylketonuria (PKU)

This infographic, which supports the poster presented at SIMD 2026, describes interim results from the Phase 3 APHENITY Extension Study evaluating diet liberalization and health-related quality of life (HRQoL) in sepiapterin-treated individuals with phenylketonuria (PKU) who were receiving sapropterin at study entry

This poster, presented at SIMD 2026, describes interim results from the Phase 3 APHENITY Extension Study evaluating diet liberalization and health-related quality of life (HRQoL) in sepiapterin-treated individuals with phenylketonuria (PKU) who were receiving sapropterin at study entry

This poster, presented at SIMD 2026, highlights interim results from the Phase 3 APHENITY Extension Study evaluating the long-term safety and responsiveness of sepiapterin treatment in children aged ≤2 years with phenylketonuria (PKU)

This poster, presented at ACMG 2025, describes interim results from the ongoing APHENITY extension study, which evaluated the effect of sepiapterin on dietary Phe tolerance in a broad population of phenylketonuria (PKU) participants

This poster, originally given as an oral presentation at ACMG 2026, summarizes results from three Phase 3 clinical trials that assessed sepiapterin responsiveness in patients with phenylketonuria (PKU)

This ICIEM 2025 oral presentation provides an overview of the AMPLIPHY phase 3 study which compares the efficacy and safety of sepiapterin and sapropterin in children and adults with phenylketonuria (PKU)

This symposium, presented at ICIEM 2025, provides an overview of sepiapterin as a treatment for phenylketonuria (PKU) and the current PKU disease landscape

This symposium, presented at ACMG 2025, summarizes the APHENITY study which assessed the effectiveness of sepiapterin on dietary Phe in a broad population of phenylketonuria (PKU) patients, and discusses the need for innovative treatment approaches